Reinventing Autoimmune Disease & Cancer Treatment by Harnessing NK Cells

Time: 11:30 am
day: Day Two


  • Validated Flex-NK™ bispecific antibody scaffold for developing next generation of NK cell redirected antibody therapeutics for Autoimmune disease and Cancer
  • CD38 a well differentiated target for B cell mediated autoimmune diseases and the unique mechanism of action of CYT-338 NK cell engaged
  • Cytovia 2.0 emerging pipeline based on NK cell therapy’s for the treatment of autoimmune and cancer indications